Communiqués Vernalis

Actions

VER

Recherche biotechnologique et médicale

Temps Différé London S.E. Autres places de cotation			Varia. 5j.	Varia. 1 janv.
- ^GBX	-.--%		+0,65%	-29,32%

Communiqués

14/12/17	Vernalis : AGM Statement	PU
14/12/17	Vernalis PLC: AGM Statement	MW
13/12/17	Vernalis : enters into research collaboration with Daiichi Sankyo	PU
13/12/17	Vernalis : + Daiichi Sankyo Enter Collaboration	MW
06/12/17	Vernalis : and Servier Achieve Research Milestone in Third Oncology Collaboration	PU
06/12/17	Vernalis : and Servier Achieve Research Milestone	MW
12/09/17	Vernalis : Results Announcement for the year ended 30 June 2017	PU
12/09/17	Vernalis plc: Results Announcement for the year ended 30 June 2017	MW
07/08/17	Vernalis PLC: FDA Issues Complete Response Letter on CCP-08 NDA	MW
18/07/17	Vernalis PLC: Year-End Trading Update and Notice of Full Year Results	MW
21/04/17	Vernalis : receives a $2 million milestone payment from one of its drug discovery collaborations	PU
21/04/17	Vernalis : FDA Issues a Complete Response Letter on CCP-07 NDA	PU
21/04/17	Vernalis PLC: FDA Issues a Complete Response Letter on CCP-07 NDA	MW
29/03/17	Vernalis : Block listing Interim Review	PU
06/03/17	Vernalis : and Servier enter into a new drug discovery collaboration strengthening their existing partnership	PU
06/03/17	Vernalis : New drug discovery collaboration with Servier	PU
21/02/17	Vernalis PLC: Unaudited Interim Results for the six months ended 31 December 2016	MW
14/02/17	Vernalis : achieves a $3 million milestone payment from Corvus Pharmaceuticals Inc	MW
30/01/17	Vernalis PLC: Notice of Results for Six Months Ended 31/12/2016	MW
30/01/17	Vernalis : Notice of Results for the Six Months Ended 31 December 2016	PU
21/12/16	Vernalis : FDA accepts CCP-08 NDA for full review	PU
21/12/16	Vernalis PLC: FDA accepts CCP-08 NDA for full review	MW
01/12/16	Vernalis plc: AGM Statement	MW
24/10/16	Vernalis : Notice of Annual Report and AGM	PU
29/09/16	Vernalis : Results Announcement for the 12 months ended 30 June 2016	PU